SCM
KTTA icon

Stonepine Capital Management’s Pasithea Therapeutics KTTA Stock Holding History

Stonepine Capital Management’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
2,201,468
+1,370,167
+165% +$943K 0.64% 36
2026
Q1 		$617K Buy
831,301
+556,239
+202% +$465K 0.25% 52
2025
Q4 		$355K Buy
+275,062
New +$242K 0.26% 54

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Stonepine Capital Management's KTTA Position: Q2 2026 in Review

Stonepine Capital Management increased its Pasithea Therapeutics (KTTA) stake by 165% in Q2 2026, buying an estimated $943K and bringing the position to 2,201,468 shares worth $1.13M. The position accounts for 0.64% of the portfolio, ranked #36.

Stonepine Capital Management first reported a position in KTTA in Q4 2025 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Stonepine Capital Management held 2,201,468 shares of Pasithea Therapeutics worth $1.13M as of Q2 2026.
  • Stonepine Capital Management bought 1,370,167 Pasithea Therapeutics shares in Q2 2026, an estimated $943K.
  • Pasithea Therapeutics made up 0.64% of Stonepine Capital Management's portfolio in Q2 2026, its #36 holding.
  • Stonepine Capital Management first reported a position in Pasithea Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.